Last updated: October 6, 2026
VEPESID is the branded oral formulation of etoposide, a topoisomerase II inhibitor used primarily in small-cell lung cancer and testicular cancer. Its commercial trajectory is mature and predominantly generic. The product’s original regulatory and patent protection has expired, standalone VEPESID revenue is not publicly reported, and current market value is concentrated in low-cost generic etoposide capsules and injectable formulations rather than the legacy brand.
What is VEPESID and how is it used?
VEPESID contains etoposide, a semisynthetic podophyllotoxin derivative that inhibits topoisomerase II and causes DNA strand breaks. The product was developed as an oral oncology treatment and was marketed by Bristol-Myers Squibb.
| Attribute |
VEPESID |
| Active ingredient |
Etoposide |
| Drug class |
Topoisomerase II inhibitor |
| Dosage forms |
Oral capsules; etoposide is also available as injection |
| Historical brand owner |
Bristol-Myers Squibb |
| FDA regulatory pathway |
Original new drug application |
| Principal indications |
Small-cell lung cancer; testicular cancer |
| Therapeutic category |
Cytotoxic oncology |
| Current commercial status |
Mature product with generic competition |
| Biosimilar status |
Not applicable; etoposide is a small molecule |
| Patent position |
Original product and composition protection expired |
The FDA labeling for VEPESID identifies its use in combination regimens and in patients with refractory testicular tumors and small-cell lung cancer. Oral etoposide has lower and more variable bioavailability than intravenous etoposide, which has limited its role in some treatment settings compared with injectable products (U.S. Food and Drug Administration [FDA], n.d.-a).
When did VEPESID lose market exclusivity?
VEPESID lost meaningful exclusivity decades ago. The product was approved in the early 1980s, placing its original small-molecule exclusivity and patent life well before the current market period.
The relevant commercial milestones are:
| Period |
Market event |
| Early 1980s |
FDA approval of oral VEPESID |
| 1990s and earlier |
Original product and formulation protection expired or became commercially irrelevant |
| 1990s-2000s |
Generic etoposide products expanded |
| 2010s |
Etoposide became a mature oncology generic |
| 2020s |
Market supplied mainly through generic capsule and injectable products |
FDA small-molecule products receive five years of new chemical entity exclusivity, subject to statutory exceptions. VEPESID’s approval predates the modern commercial environment in which branded oncology products maintain value through later patents, pediatric exclusivity, or extended-release reformulations. No current exclusivity period materially protects the VEPESID brand (FDA, n.d.-b).
What patents protect VEPESID?
No commercially material, unexpired patent estate is associated with the original VEPESID product.
The original intellectual-property position would have covered the etoposide active ingredient, pharmaceutical compositions, manufacturing methods, and possibly oral dosage forms. Those rights have long since expired. The product is not comparable to a newer oncology therapy protected by active composition-of-matter patents or a dense Orange Book formulation portfolio.
Orange Book status
The FDA Orange Book is the principal source for listed patents and regulatory exclusivity associated with approved drug products. For a mature product such as VEPESID, the important distinction is between:
- The historical reference product and its regulatory approval.
- Current generic approvals for etoposide.
- Any active patents listed against a specific generic or branded presentation.
The commercial record does not indicate a current VEPESID patent barrier capable of preventing abbreviated new drug application approval or generic substitution. Any current patent issue would more likely concern a particular manufacturer’s manufacturing process, injectable container, excipient system, or newer delivery technology rather than the legacy VEPESID product itself (FDA, n.d.-c).
How many patents cover VEPESID today?
The commercially relevant number is effectively zero for the legacy oral product’s core market position. Historical etoposide patents may still appear in patent databases because patent records remain publicly accessible after expiration, but expired rights do not block generic entry.
Potential patent categories include:
| Patent category |
Present commercial impact |
| Etoposide composition patents |
Expired |
| Original oral capsule patents |
Expired |
| Conventional injectable formulation patents |
Expired or nonblocking |
| Manufacturing process patents |
May exist for individual suppliers but do not recreate brand exclusivity |
| New delivery systems |
Potentially relevant only to separate products |
| Method-of-use patents |
No known broad, active VEPESID barrier |
| Packaging or device patents |
Limited product-specific relevance |
What is the FDA regulatory status of VEPESID?
VEPESID is an established FDA-approved etoposide product, but the brand is no longer the primary commercial focus of the market. The FDA’s regulatory framework now centers on approved etoposide products supplied by multiple manufacturers.
Etoposide is also available as an injectable product under different brand and generic names. The injectable form is commonly used in hospital oncology protocols because it allows controlled administration and integration into combination chemotherapy regimens. Oral capsules remain relevant where outpatient administration, treatment continuity, or a prescribed oral regimen is preferred.
FDA-regulated risks include severe myelosuppression, secondary leukemia, hypersensitivity reactions, mucositis, nausea, alopecia, and infection risk. These safety characteristics affect prescribing and monitoring costs but do not create a current exclusivity advantage for VEPESID (FDA, n.d.-a; National Cancer Institute, n.d.).
Which companies compete with VEPESID?
VEPESID competes primarily with generic etoposide manufacturers rather than with another branded oral product.
Generic manufacturers and market participants
The U.S. supplier base has included major generic and specialty pharmaceutical companies that manufacture or distribute etoposide capsules or injection. The exact supplier list changes as companies exit low-margin oncology products, transfer approvals, or experience manufacturing disruptions.
The competitive structure has several characteristics:
- Multiple approved generic suppliers reduce brand pricing power.
- Injectable etoposide is purchased mainly through hospitals, group purchasing organizations, wholesalers, and specialty distributors.
- Oral etoposide has a smaller and more specialized demand base than injectable etoposide.
- Supply interruptions can produce temporary pricing increases even after patent expiry.
- Active pharmaceutical ingredient availability and sterile manufacturing capacity are more important for injection than for capsules.
The leading competitive threat is substitution by FDA-approved generic etoposide, not replacement by a biosimilar or a new branded version of VEPESID.
What generic entry risks exist for VEPESID?
Generic entry risk is complete and structural. The market has already moved beyond the Paragraph IV-driven launch phase into long-term generic competition.
Paragraph IV challenges
Paragraph IV certification is used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or would not be infringed. It is most relevant before the reference product’s listed patents expire.
For VEPESID, any historical Paragraph IV activity would have had commercial importance during the initial genericization period. It has little current impact because the core patent and exclusivity period ended long ago. Current generic suppliers do not need to overcome an active VEPESID patent barrier to compete with the legacy product.
Generic launch scenarios
The likely market scenarios are:
| Scenario |
Commercial result |
| Stable multi-source supply |
Continued price erosion and low brand share |
| One or more supplier exits |
Temporary shortages and higher generic pricing |
| Hospital purchasing consolidation |
Greater pressure on supplier margins |
| Increased oral chemotherapy use |
Modest volume support for capsules |
| New oral oncology alternatives |
Further erosion of VEPESID demand |
| Manufacturing disruption |
Short-term supply volatility, not durable brand recovery |
VEPESID could retain limited use where physicians prescribe the brand, pharmacies have historical purchasing relationships, or payer arrangements create an exception. Those factors do not restore meaningful exclusivity.
What formulations are protected by VEPESID patents?
No active VEPESID formulation patent is known to protect the conventional oral capsule market. Etoposide capsules are technically less complex than many modern oncology products, although the active ingredient’s low and variable oral bioavailability creates formulation and quality-control requirements.
The principal formulation issues are:
- Capsule strength and dose uniformity.
- Dissolution and bioavailability.
- Stability of the active ingredient.
- Excipient compatibility.
- Consistent absorption across patients.
- Safe handling of a cytotoxic compound.
These requirements can create regulatory and manufacturing barriers, but they are not equivalent to patent exclusivity. A generic manufacturer must demonstrate pharmaceutical equivalence and meet FDA quality standards, but it does not need to license VEPESID technology.
How strong is the VEPESID patent estate?
The VEPESID patent estate is weak from a current investment or litigation perspective because:
- Core product patents have expired.
- The drug is a long-established small molecule.
- Generic alternatives are available.
- No current exclusivity period supports premium pricing.
- The product has no biologic component requiring biosimilar protection.
- Formulation differentiation is limited.
The stronger barriers are operational rather than legal. Manufacturers must maintain compliant oncology production, secure active pharmaceutical ingredient supply, satisfy quality requirements, and manage cytotoxic handling controls. These barriers may reduce the number of active suppliers, but they do not prevent substitution in the same way as a live composition patent.
What patent litigation affects VEPESID?
There is no widely recognized current patent litigation that materially threatens or protects the VEPESID brand. The relevant litigation risk is more likely to involve:
- Generic manufacturer manufacturing processes.
- Sterile injectable production.
- Supply contracts and shortages.
- Product liability claims.
- ANDA disputes involving a particular generic supplier.
- Patent claims covering new etoposide delivery technologies.
Legacy litigation surrounding etoposide patents would have been most relevant during generic entry. It does not appear to define the current market.
Does VEPESID face biosimilar competition?
No. Biosimilars apply to biological products, while VEPESID contains etoposide, a chemically synthesized small molecule. Competition occurs through generic drug approval pathways, primarily ANDAs, rather than through the Public Health Service Act biosimilar pathway.
This distinction matters commercially. Generic etoposide can compete directly on pharmaceutical equivalence and price. A biosimilar would involve a different regulatory framework, more complex comparability requirements, and a separate substitution analysis.
What is the financial trajectory for VEPESID?
VEPESID’s financial trajectory is a classic mature-product decline:
- Initial branded revenue during the protected period.
- Gradual erosion as oncology protocols and generic alternatives expanded.
- Sharp price and share pressure after generic entry.
- Residual brand demand in selected channels.
- Limited strategic value relative to newer oncology products.
Bristol-Myers Squibb does not publicly report VEPESID as a standalone revenue line in its current corporate disclosures. The company reports financial performance by broader products, therapeutic areas, and operating segments rather than providing a separate current revenue series for VEPESID. A precise brand-level revenue history therefore cannot be derived from public annual reports.
Revenue exposure
The economic exposure is likely modest for the original brand owner but meaningful for the broader etoposide supply chain. Revenue is distributed among:
- Generic capsule manufacturers.
- Injectable oncology suppliers.
- Wholesalers and specialty distributors.
- Hospital systems and group purchasing organizations.
- Contract manufacturers and active pharmaceutical ingredient suppliers.
For branded VEPESID, the key financial risks are low volume, generic substitution, reimbursement pressure, and limited ability to raise prices. For generic suppliers, profitability depends on manufacturing efficiency, reliable supply, and avoiding quality-related interruptions.
How does VEPESID compare with newer oncology drugs?
| Factor |
VEPESID |
Newer targeted or immune-oncology drugs |
| Patent protection |
Expired |
Often active |
| Market structure |
Multi-source generic |
Branded or limited competition |
| Price level |
Low relative to novel agents |
High |
| Revenue growth |
Mature or declining |
Can expand rapidly after launch |
| Clinical use |
Established chemotherapy protocols |
Biomarker- or disease-specific use |
| Regulatory risk |
Manufacturing and safety compliance |
Clinical, regulatory, and lifecycle risk |
| Commercial differentiation |
Limited |
Often based on efficacy, biomarker, or delivery |
| Biosimilar exposure |
Not applicable |
Relevant for biologics |
| Payer leverage |
Strong |
Variable, often weaker during exclusivity |
VEPESID remains clinically useful because low-cost cytotoxic agents retain a role in combination therapy. Clinical utility does not translate into strong brand economics once generic alternatives are available.
What licensing deals affect VEPESID?
No major current licensing transaction is publicly associated with VEPESID that materially changes its market position. The product’s commercial rights historically reflected the originator’s development and marketing structure. In the current market, licensing value would be limited unless tied to:
- A novel oral delivery technology.
- A controlled-release formulation.
- A new combination regimen.
- A specialized regional distribution agreement.
- A manufacturing or supply arrangement.
The legacy brand alone is unlikely to command material licensing economics because generic substitution is established and the core patent estate has expired.
What geographic markets still use VEPESID?
Etoposide is used internationally in oncology, although product names, suppliers, strengths, and regulatory classifications differ by jurisdiction. The principal geographic markets are North America, Europe, Japan, and emerging oncology markets where standard chemotherapy remains important because of its clinical familiarity and lower cost.
Geographic commercial factors include:
- Local generic approval requirements.
- Hospital procurement systems.
- National reimbursement policies.
- Availability of injectable oncology products.
- Local shortages and import dependence.
- Differences in brand prescribing and substitution rules.
A brand may retain stronger recognition outside the United States, but international use does not create global exclusivity. Patent rights are territorial, and the original etoposide protection has generally expired across major markets.
Key Takeaways
- VEPESID is the legacy branded oral etoposide product associated with Bristol-Myers Squibb.
- Its core patents and regulatory exclusivity expired decades ago.
- The current market is dominated by generic etoposide capsules and injectable products.
- No biosimilar pathway applies because etoposide is a small molecule.
- Current Paragraph IV activity is not a material commercial barrier to generic competition.
- No active VEPESID formulation estate is known to support premium pricing.
- Standalone VEPESID revenue is not disclosed by Bristol-Myers Squibb.
- Financial value has shifted from the brand to generic supply, manufacturing reliability, and hospital procurement.
- Supply disruptions can create temporary pricing volatility, but they do not restore durable brand exclusivity.
- The product remains clinically relevant while offering limited branded investment upside.
FAQs
Is VEPESID still sold in the United States?
Etoposide remains available in the United States, primarily through generic capsule and injectable products. The commercial presence of the VEPESID brand is substantially smaller than during its protected period.
Is VEPESID the same as etoposide?
Yes. VEPESID is a brand name for etoposide. Generic etoposide products contain the same active pharmaceutical ingredient but may be supplied by different manufacturers.
Can a generic company launch etoposide without a VEPESID license?
Yes. A generic manufacturer does not need a VEPESID license when the relevant patents have expired. It must obtain the required FDA approval and meet applicable quality, equivalence, labeling, and manufacturing standards.
Why does injectable etoposide have greater commercial relevance than oral VEPESID?
Injectable etoposide is integrated into hospital chemotherapy protocols and allows controlled administration. Oral etoposide has more variable absorption and is used in narrower treatment settings.
Is VEPESID a growth product for pharmaceutical investors?
No. VEPESID is a mature genericized oncology product. Investment exposure is more likely to arise from manufacturing scale, supply reliability, shortage dynamics, or a differentiated etoposide delivery system than from the legacy brand.
References
-
National Cancer Institute. (n.d.). Etoposide. https://www.cancer.gov/about-cancer/treatment/drugs/etoposide
-
U.S. Food and Drug Administration. (n.d.-a). VEPESID (etoposide) capsules prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). New drug product exclusivity. FDA. https://www.fda.gov/drugs/development-resources/new-drug-product-exclusivity
-
U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Bristol-Myers Squibb Company. (2024). Annual report. https://www.bms.com/investors/annual-reports.html
